West Analytical Services LLC has introduced a testing platform to help mitigate the risks associated with testing pulmonary and nasal drug products and their delivery devices. The company’s analytical services for pulmonary and nasal drug products include early-stage development, clinical development and post-product launch stages for pharma, biopharma and medical device clients. West provides testing for: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), nasal and oral sprays, and nebulizers at its FDA-registered, cGMP lab in Lionville, PA.
   
“Moving pulmonary and nasal drug products from early-stage development to the market is challenging for pharmaceutical, biopharmaceutical and medical device companies,” said Fran DeGrazio, vice president, marketing and strategic business development. “The challenges include testing the drug product and delivery device. Companies may not have a proven device selection process in place and may not have validated laboratory methods or instruments required to test the drug product and the device. Any misstep along the way runs the risk of costly project delays.”